

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number
WO 2005/047318 A1

(51) International Patent Classification⁷: **C07K 14/47**,
G01N 33/68

(21) International Application Number:
PCT/GB2004/004749

(22) International Filing Date:
11 November 2004 (11.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/519,190 11 November 2003 (11.11.2003) US
60/607,010 3 September 2004 (03.09.2004) US

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BOSTWICK, Robert James** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **CORRADI, John** [US/US]; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **DEFAY, Thomas** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **FURLONG, Stephen** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **HIRATA, Lee T** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19852-5437 (US).

RAVYN, Vipa [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **ROBBINS, Alan** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **GNAL SPLICE VARIANT AND USES THEREOF**



(57) Abstract: The present invention relates to a novel splice form of the GNAL gene product and methods for identifying modulators of G protein coupled receptors.